Pharmland is here to serve up the freshest pharmacy information and insights to benefits advisors, employers, and anyone else looking for a better understanding of the industry. Pharmacy – prices, policy, politics, and so much more – can be opaque and confusing, and we think it shouldn’t be. We think making informed decisions and moving confidently in the pharmacy space requires clarity and transparency. That’s why our experts take the biggest topics and dig deep, getting right to the root of it all, offering perspectives you won’t find anywhere else, making the subject accessible to the people impacted by it the most.
GLP-1s: The Hefty Cost Driver That Shows No Signs of Growing Leaner
GLP-1 utilization continues to balloon. With their demonstrated strong performance in treating conditions such as diabetes and certain cardiovascular risks, as well as their potential for lifestyle-related weight loss, the market for GLP-1s has truly skyrocketed, growing from a $46.7 billion market in 2024 to a mind-boggling projected $471 billion market by 2032. And these “hot” drugs are only getting hotter. Not only are direct-to-consumer advertising, celebrity promotion, and social media continuing to influence demand, but GLP-1s are also being explored to help solve a growing plethora of healthcare needs. On the horizon? New approvals for additional indications, new pathways of action, and GLP-1s as part of combination therapies. In other words, GLP-1s will remain buzzworthy for a long time to come – and given their price tags, employers need to be prepared. This episode will explore what employers need to know about the GLP-1 trend and what they can do to stay ahead of emerging trends and potential impacts of this already significant trend driver. Hosts:
Bradley Nelson, PharmD, Vice President, Clinical Services
Tom Davies, PharmD, Medicaid Pharmacy Director, Utah Department of Health and Human Services; Former Vice President, Clinical Products at RxBenefits
28 Aug 2025
Signed, Sealed…Surprised? The Case for Transparency in Pharmacy Benefits
Hidden fees. Spread pricing. Rebate retention. The fine print in pharmacy benefits contracts can quietly drive costs higher for employers and employees alike. In this episode of Pharmland, co-hosts Bradley Nelson and Tom Davies talk with RxBenefits Senior Director and Managing Counsel Wes Hill to break down the opaque practices that can keep pharmacy benefits costs high and clarity low – and make the case for how true transparency can protect budgets and improve member outcomes.
Hosts:
Bradley Nelson, PharmD, Vice President, Clinical Services
Tom Davies, PharmD, Vice President, Clinical Products
Guest:
Wes Hill, Sr. Director, Managing Counsel, Regulatory & Intellectual Property
25 Jun 2025
Pharmacy Benefits in Flux: How State Regulations Are Reshaping the Industry
Wes Hill, Sr. Director, discusses the evolving state pharmacy regulations and their potential impact on patient benefits, employer costs, and the pharmacy industry with hosts Bradley Nelson, PharmD, and Tom Davies, PharmD, in an interview.
29 Apr 2025
The $471 Billion Question: What's next for employers on the GLP-1 rollercoaster?
Join Bradley Nelson and Tom Davies for the latest episode of Pharmland as they tackle the $471 billion question – what’s driving the GLP-1 craze in 2025? From new approvals for chronic kidney disease and certain cardiovascular conditions to potential further expanded indications for conditions like non-alcoholic steatohepatitis (NASH) and Alzheimer’s, learn how these revolutionary drugs are reshaping the pharmaceutical market, what they mean for the future of innovation, and the potential impact on plan sponsors and patients.
12 Feb 2025
From Concept to Cure: The Journey of a New Drug and Its Cost Impact
In this episode of Pharmland, co-hosts Bradley Nelson and Tom Davies explore the long and often arduous journey of drug development – from early clinical trials to U.S. Food and Drug Administration (FDA) approval and beyond. Learn more about how pharmaceutical companies decide which drugs to pursue, why only 10% of potential therapeutic agents make it to market as a new drug, and how that impacts the price of a drug and therefore, pharmacy plans.
13 Nov 2024
Complicated Pharmacy Math: Factors that Impact a Patient’s OOP Cost
What factors impact a patient’s cost at the pharmacy counter?
In this episode of Pharmland, co-hosts Bradley Nelson and Tom Davies dive into the complex world of the out-of-pocket cost a patient pays at the pharmacy and explore the forces that contribute to medication costs – from high-deductible health plans to formulary tiers, rebates, and PBM negotiations – and can lead to some major shock at the price tag. Listen as Bradley and Tom explain why more patients are facing tough decisions at checkout – and what can be done to help them make informed choices.
Hosts:
Bradley Nelson, PharmD, Vice President, Clinical Services
Tom Davies, PharmD, Vice President, Clinical Products
23 Sept 2024
What the WAC? Decoding Pharmacy Pricing from Manufacturer to Pharmacy
“Where do different pharmacy pricing points fit in the life cycle of prescription drugs?”
In this episode of Pharmland, co-hosts Bradley Nelson and Tom Davies examine the intricacies of drug pricing. They break down how pricing evolves through the supply chain – from the manufacturer to the pharmacy – and explain key terms like Wholesale Acquisition Cost (WAC), Maximum Allowable Cost (MAC), and Average Wholesale Price (AWP). Gain a clearer understanding of how these costs influence drug costs and impact your pharmacy benefits strategy.
Hosts:
Bradley Nelson, PharmD, Vice President, Clinical Services
Tom Davies, PharmD, Vice President, Clinical Products
23 Aug 2024
Pharmacy Plan Playbook: Goals, Strategies, and Smart Moves
How to evaluate what to consider when developing a pharmacy plan, including the pharmacy benefit landscape, potential member impact from pharmacy plan changes, and how geography or industry can influence usage trends for high-cost medications like GLP1s. The conversation highlights how to balance what is important to your organization and employees with cost containment strategies.
15 Jul 2024
Bio, Are They Really That Similar?
“Why are biosimilars taking so long to catch on?”
In this episode of Pharmland, co-hosts Bradley Nelson and Tom Davies talk with RxBenefits Clinical Services Principal Advisor about a hot topic within the pharmacy industry: biosimilars. The experts explore biosimilars and their role in the pharmacy landscape, including how they can help mitigate skyrocketing specialty drug costs and why there hasn’t been an uptick in usage the way many experts expected. Tune in as they discuss what exactly a biosimilar is, as well as what the future holds for them and their place in the market.
Guest:
Ruth Opdycke, PharmD, Principal Advisor, Clinical Services
Co-hosts:
Bradley Nelson, PharmD, Vice President, Clinical Services
Tom Davies, PharmD, Vice President, Clinical Products
7 Jun 2024
Prior Authorizations: Are They Evil or Good?
S01 E04: Prior Authorizations: Are They Evil or Good?
“What’s the reason behind a prior authorization?”
In this episode of Pharmland, co-hosts Bradley Nelson and Tom Davies talk with RxBenefits Clinical Operations Manager Lindsay Miller about the intricate world of prior authorizations. They explore the complexities and challenges surrounding this critical process in healthcare, highlighting its impact on patients, providers, and payers alike. Tune in as they discuss strategies for streamlining prior authorization procedures, the balance between cost control and patient access, and the future of this pivotal aspect of pharmacy benefits management.
Guest:
Lindsay Miller (https://www.linkedin.com/in/lindsay-miller-a03bb826/) ,PharmD, Manager, Clinical Pharmacists
Co-hosts:
Bradley Nelson (https://www.linkedin.com/in/j-bradley-nelson-74861513/), PharmD, Vice President, Clinical Services
Tom Davies (https://www.linkedin.com/in/thomas-davies-1b591abb/), PharmD, Vice President, Clinical Products
3 May 2024
GLP Indication #1 : Balancing guidelines and individualized treatment
GLP Indication #1 : Balancing guidelines and individualized treatment
“Should physicians rigidly adhere to treatment guidelines or prioritize accommodating patient preferences?”
Join hosts Bradley Nelson and Tom Davies, alongside RxBenefits clinical pharmacist Langley Kyle, PharmD, as they discuss balancing GLP-1 treatment guidelines with individualized patient care, particularly for those with comorbidities, as well as the evolution of GLP-1s and their impact.
In this episode, the team explores how GLP-1 medications have transformed diabetes treatment over the past decade, including offering patients more convenient dosing options. They discuss practical strategies for plan sponsors to support medication adherence and lifestyle changes in support of disease management. And tackle an important issue that can result from class popularity – drug shortages.
Guest:
Langley Kyle (https://www.linkedin.com/in/langley-kyle-673029148/), PharmD, Director, Clinical Services
Co-hosts:
Bradley Nelson (https://www.linkedin.com/in/j-bradley-nelson-74861513/), PharmD, Vice President, Clinical Services
Tom Davies (https://www.linkedin.com/in/thomas-davies-1b591abb/), PharmD, Vice President, Clinical Products
4 Apr 2024
Oh, Oh...Overpromise? The Truth Beyond the GLP-1 Trend
S01 E01: Oh, Oh...Overpromise? The Truth Beyond the GLP-1 Trend
“What’s really driving the interest around the phenomenon that we currently label as GLP-1s?”
In this episode of Pharmland, hosts Bradley Nelson and Tom Davies dive deep into the world of GLP-1 medications for weight loss alongside RxBenefits clinical pharmacist Langley Kyle, PharmD. They tackle pressing questions surrounding the surge in GLP-1 utilization, from the impact of direct-to-consumer marketing and celebrity endorsements to concerns about sustainability and potential side effects. Join them as they unravel the complexities of this pharmaceutical phenomenon and explore whether the promises made by these medications truly stand up to scrutiny.
Guest:
Langley Kyle (https://www.linkedin.com/in/langley-kyle-673029148/), PharmD, Director, Clinical Services
Co-hosts:
Bradley Nelson (https://www.linkedin.com/in/j-bradley-nelson-74861513/), PharmD, Vice President, Clinical Services
Tom Davies (https://www.linkedin.com/in/thomas-davies-1b591abb/), PharmD, Vice President, Clinical Products
4 Mar 2024
Wait… Weight, What? Getting the Skinny on GLP-1s for Weight Management
S01 E01: Wait… Weight, What? Getting the Skinny on GLP-1s for Weight Management
“Why is weight-loss achievement the holy grail of drug development?”
In the premiere episode of Pharmland, co-hosts Bradley Nelson and Tom Davies talk with RxBenefits clinical pharmacist Langley Kyle, PharmD, about the use of GLP-1 drugs for weight-loss purposes — and discuss society’s changing attitudes toward obesity. As the healthcare industry comes to recognize obesity as a treatable health condition rather than a personal failing, plan sponsors find themselves examining their position on covering weight-loss medications as a class. And as GLP-1s originally indicated for type 2 diabetes are increasingly used for weight-management purposes, that decision — to cover, or not to cover? — becomes increasingly pricey.
Guest:
Langley Kyle (https://www.linkedin.com/in/langley-kyle-673029148/), PharmD, Director, Clinical Services
Co-hosts:
Bradley Nelson (https://www.linkedin.com/in/j-bradley-nelson-74861513/), PharmD, Vice President, Clinical Services
Tom Davies (https://www.linkedin.com/in/thomas-davies-1b591abb/), PharmD, Vice President, Clinical Products
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
5.0 / 5
10 ratings
Podcast Authority Score: 15 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
10
Social presence
0
YouTube
0
Engagement
51
Contact Pharmland
Guest appearances
Does not typically book guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Pharmland?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
